Hybio Pharmaceutical Co.Ltd(300199) reply to the inquiry letter: covid-19 nasal spray drug of the company "is in the stage of rapid development" is described accurately

On April 13, Hybio Pharmaceutical Co.Ltd(300199) replied to the inquiry letter of Shenzhen Stock Exchange: in parallel with other covid-19 specific drug R & D projects developed based on polypeptide technology platform in China, the polypeptide nasal spray project of the company has lasted five months since the signing of the patent licensing agreement in November 2021. According to the current progress, it is in the process of in vivo efficacy research, in vivo pharmacology and toxicology research, safety evaluation research and sample production under GMP conditions. Based on the above research and development progress, the company believes that covid-19 nasal spray drug is accurately described as "in the stage of rapid development".